Royalty Pharma (MEX:RPRX) Other Current Payables : MXN1,558 Mil (As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Other Current Payables?

Royalty Pharma's Other Current Payables for the quarter that ended in Sep. 2024 was MXN1,558 Mil.

Royalty Pharma's quarterly Other Current Payables increased from Mar. 2024 (MXN1,517 Mil) to Jun. 2024 (MXN1,805 Mil) but then declined from Jun. 2024 (MXN1,805 Mil) to Sep. 2024 (MXN1,558 Mil).

Royalty Pharma's annual Other Current Payables declined from Dec. 2021 (MXN2,214 Mil) to Dec. 2022 (MXN1,848 Mil) and declined from Dec. 2022 (MXN1,848 Mil) to Dec. 2023 (MXN1,411 Mil).

Royalty Pharma Other Current Payables Historical Data

The historical data trend for Royalty Pharma's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Other Current Payables Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Current Payables

Get a 7-Day Free Trial

585.43

2,513.67

2,214.16

1,848.28

1,411.49

Royalty Pharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Current Payables	Get a 7-Day Free Trial															1,771.69	1,411.49	1,517.05	1,805.26	1,558.47

Royalty Pharma Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Royalty Pharma Other Current Payables Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Other Current Payables provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (MEX:RPRX) » Definitions » Other Current Payables

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPD:Germany

Address

110 East 59th Street, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.